Dr Linton - Epcor in RR FL
• pivotal P2 study
• high risk group
• ORR 82%, CMR 69%
• similar responses in high risk pts
• CRS lower with optimised step up
No access yet to bispecific Ab is RR FL in 🇬🇧- might this change?

#BSH24 #lymsm

$MREO Similar asset as Navi. Our program valued at zero basically. Compass about a $200mkt cap When will this insanity end with DSK.
$CMPX
CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients…

This year's #PM2024 will be a virtual webinar on the topic of Operationalizing Bispecific T-Cell Engagers, and we're seeking presenters. Applications open through May 19. To apply and find out more, visit bit.ly/3UExjLq

Bispecific T cell engagers (BiTEs) recruit T cells to target cells - usually B cells, in cancer - to deplete the targets

This study repurposed BiTEs for rheumatoid arthritis, an autoimmune condition driven by B cells

It's a small, single arm study of 6 patients, who had…

『Bispecific T cell engager therapy for refractory rheumatoid arthritiS』

Nature Medicine 　26 April 2024

ブリナツモマブは、すべての患者においてRAの臨床活動期の迅速な低下をもたらし、超音波およびFAPI-PET-CTでの滑膜炎改善、自己抗体減少を達成しました。

Newly published Blood Journal: consensus guidelines on toxicity management with bispecific antibodies. Congratulations to our lymphoma chief Dr. manalikamdar on contributing to this critical #lymsm manuscript. cc CU Anschutz Division of Hematology
ashpublications.org/blood/article/…

7 patients with Glanzmann Thrombasthenia have been dosed with the bispecific antibody HMB-001. Dosing likely to be every 14 days or less.

linkedin.com/pulse/bispecif…

$ALPMY
- Astellas cuts a bispecific in cancer and a mitochondria-focused asset from Mitobridge deal - endpts.com/astellas-cuts-…

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificity biorxiv.org/cgi/content/sh… #biorxiv_cancer

Structural basis for bispecific antibody design: arrangement of domain linkage produces activity enhancement biorxiv.org/cgi/content/sh… #biorxiv_biochem

『Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial』

Nat Comm  20 Ap 2024

全応答率（92％）中央無病生存期間（19.7月）中央全生存期間（19.7月）応答期間中央値（未達成）

CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC #PediatricLymphoma [Video] Natasha Leighl, MD, University of Toronto, Toronto, Canada, discusses findings from the Phase Ib CHRYSALIS trial (NCT02609776) of amivantamab, an EGFR-MET bispecific… dlvr.it/T5rJbN

Our CSO Ray Jupp gave a presentation on M300, our FAPxLTBR bispecific antibody that conditionally induces TLSs for anti-tumor activity, at the Immuno UK Conference. Download our M300 poster: mestagtherapeutics.com/wp-content/upl…

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma | Blood | American Society of Hematology ashpublications.org/blood/article/…

In 6 patients with multi-drug resistant #RheumatoidArthritis , the CD19-CD3-targeting bispecific T cell engager #BiTE blinatumomab reduced disease activity and led to reductions in autoantibodies #autoimmunity Ricardo Grieshaber-Bouyer FAU Erlangen-Nbg nature.com/articles/s4159…

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody dlvr.it/T5wpz8 #FrontImmunol

IQVIA Institute
Chinese biotech companies have focused on oncology, specifically developing ADCs and Bispecific antibodies. Over the past two to three years, they have secured numerous successful deals with global pharmaceutical companies. While their ADC technology…

Global Bispecific Antibody Industry Expected to Reach US$1 Billion by 2033, Driven by Steady Growth at 7.2% CAGR | FMI - express-press-release.net/news/2024/04/2…